Talk:Sotrovimab

Pharmacology Mid‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

COVID-19 Mid‑importance

	COVID-19 portal This article is within the scope of WikiProject COVID-19, a project to coordinate efforts to improve all COVID-19-related articles. If you would like to help, you are invited to join and to participate in project discussions.COVID-19Wikipedia:WikiProject COVID-19Template:WikiProject COVID-19COVID-19 articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Sotrovimab.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Sotrovimab has a different mechanism against Omicron variants, compared to Evusheld

Sotrovimab has a different mechanism against Omicron variants, compared to Evusheld.

"Sotrovimab S309 and EvuSheld AZD7442 have different mechanisms of protection against Omicron variants, with S309 utilizing Fc effector function interactions and AZD7442 acting principally by direct neutralization".

https://www.biorxiv.org/content/10.1101/2022.03.17.484787v1

Preprint, Posted March 18, 2022.

So it would be theoretically best to give patient both antivirals, EvuSheld and Sotrovimab.

The problems or issues with Sotrovimab, compared to AstraZeneca Evusheld I can think of:

Higher price

Needs to be given intravenously. Evusheld is given as an injection to butt.

Shorter half-life? For how long does it work? So doesn't work prophylactically unlike EvuSheld, which works for several months?

Manufacturer press releases:

Sotrovimab: https://investors.vir.bio/press-releases/

EvuSheld: https://www.astrazeneca.com/media-centre/press-releases.html

--91.159.188.253 (talk) 15:04, 11 June 2022 (UTC)[reply]

Talk:Sotrovimab

Sotrovimab has a different mechanism against Omicron variants, compared to Evusheld

Navigation menu

Search